Chromosome 5p Region SNPs Are Associated with Risk of NSCLC among Women
Table 2
Associations between chromosome 5p SNPs and risk of NSCLC by race under a dominant model.
Caucasians
African Americans
Gene
SNP Identifier
Minor Allele Freq (%) Controls
Hap Map CEU Allele Freq
OR1 (95% CI)
Gene P-value2
Minor Allele Freq (%) Controls3
Hap Map ASW Allele Freq
OR1 (95% CI)
Gene P-value2
Comparison of Variant Allele Freq. P-value2
AHRR
rs34847072
2912 bp of STP G/C
0.37
N/A
0.93 (0.64–1.35)
0.10
N/A
1.03 (0.43–2.47)
<.0001
AHRR
rs10078
3152 bp of STP T/G
0.22
0.18
0.84 (0.58–1.22)
.22
0.26
0.23
0.65 (0.32–1.31)
.08
.34
TERT
rs2853690
Ex16 + 203 G/A
0.18
0.16
0.92 (0.62–1.36)
0.34
0.29
0.81 (0.40–1.60)
<.0001
TERT
rs2075786
IVS10 + 269 G/A
0.33
0.40
1.17 (0.81–1.70)
0.48
N/A
3.04 (1.26–7.30)
<.0001
TERT
rs2853677
IVS2-4455 A/G
0.44
0.42
1.76 (1.16–2.67)
0.23
0.36
2.18 (1.08–4.38)
<.0001
TERT
rs27359402
A/G
0.49
N/A
0.99 (0.66–1.49)
0.55
N/A
0.38 (0.17–0.85)
.15
TERT
rs1801075
T/C
0.16
0.18
1.00 (0.68–1.49)
.06
0.16
0.12
1.12 (0.54–2.29)
.02
1.00
SLC6A3
rs63472
S405S
0.25
0.25
1.10 (0.76–1.58)
0.55
0.48
0.68 (0.30–1.56)
<.0001
SLC6A3
rs460700
IVS4 + 2610 T/C
0.23
0.30
0.79 (0.54–1.15)
0.32
N/A
0.79 (0.40–1.57)
.01
SLC6A3
rs26525112
G/A
0.42
N/A
1.34 (0.90–2.00)
.17
0.65
N/A
0.92 (0.34–2.48)
.25
<.0001
MTRR
rs10380
H622Y
0.10
0.16
0.94 (0.59–1.49)
0.33
0.28
1.06 (0.53–2.11)
<.0001
MTRR
rs1802059
A664A
0.39
0.31
0.88 (0.61–1.28)
0.26
0.32
1.02 (0.52–2.02)
.002
MTRR
rs9332
Ex15-526 G/A
0.11
0.19
1.01 (0.65–1.56)
0.37
0.33
1.01 (0.50–2.03)
<.0001
MTRR
rs86592
Ex15-405 A/T
0.36
0.46
1.04 (0.72–1.51)
.81
0.51
N/A
0.90 (0.40–2.04)
.89
.0001
AMACR
rs2278008
K277E
0.26
0.20
1.14 (0.79–1.64)
0.23
0.17
0.99 (0.48–2.05)
.36
AMACR
rs840409
IVS4 + 3803 G/C
0.12
0.13
1.03 (0.66–1.59)
0.10
.04
0.59 (0.23–1.52)
.65
AMACR
rs34677
Q239H
0.15
0.15
0.98 (0.66–1.48)
0.11
.05
0.88 (0.36–2.06)
.15
AMACR
rs2287939
S201L
0.28
0.27
1.18 (0.82–1.70)
0.16
0.20
0.67 (0.31–1.44)
.0009
AMACR
rs109411122
D175G
0.48
0.44
1.20 (0.80–1.82)
0.89
0.88
1.54 (0.18–13.08)
<.0001
AMACR
rs346892
IVS1 + 169 A/C
0.18
0.17
1.03 (0.70–1.52)
.63
0.50
0.47
0.58 (0.27–1.25)
.02
<.0001
GHR
rs2972395
C/T
0.21
0.10
0.88 (0.60–1.28)
0.22
N/A
1.00 (0.48–2.08)
.83
GHR
rs2940930
G/A
0.36
0.36
0.76 (0.52–1.11)
0.14
0.16
1.72 (0.84–3.53)
<.0001
GHR
rs7732059
G/C
0.22
N/A
1.29 (0.90–1.87)
0.32
N/A
1.30 (0.65–2.59)
.01
GHR
rs1858136
IVS1 + 12052 G/C
0.21
0.10
0.86 (0.59–1.26)
0.26
N/A
0.69 (0.34–1.40)
.15
GHR
rs29724182
IVS1 + 59636 T/C
0.48
0.50
1.12 (0.74–1.72)
0.67
0.65
0.66 (0.23–1.91)
<.0001
GHR
rs2972419
IVS1 + 59820 G/A
0.21
0.15
0.93 (0.63–1.36)
0.22
0.29
0.98 (0.47–2.02)
.87
GHR
rs29409442
IVS1 + 65085 A/C
0.46
0.49
1.25 (0.83–1.89)
0.58
0.56
1.14 (0.48–2.72)
.004
GHR
rs29723922
IVS1 − 70131 A/C
0.41
N/A
1.30 (0.87–1.93)
0.57
N/A
1.07 (0.46–2.52)
<.0001
GHR
rs33939197
IVS1− 69908 T/C
0.19
N/A
1.29 (0.88–1.87)
0.16
N/A
0.86 (0.39–1.90)
.34
GHR
rs29409132
IVS1− 66349 G/T
0.46
0.47
1.25 (0.83–1.89)
0.67
N/A
0.60 (0.20–1.82)
<.0001
GHR
rs7735889
IVS1− 3767 A/G
0.25
0.34
1.10 (0.76–1.58)
0.61
0.47
0.54 (0.23–1.30)
<.0001
GHR
rs7712701
IVS2 + 4144 C/A
0.23
N/A
1.20 (0.83–1.74)
0.61
N/A
0.81 (0.33–2.00)
<.0001
GHR
rs28943882
IVS2 + 29065 C/T
0.17
0.21
1.16 (0.80–1.70)
0.42
0.27
1.06 (0.52–2.15
<.0001
GHR
rs6873545
IVS3 + 2059 T/C
0.26
0.28
1.53 (1.05–2.21)
0.45
0.58
1.12 (0.53–2.38)
<.0001
GHR
rs4451056
IVS3 + 26148 G/C
0.15
0.18
1.49 (1.01–2.20)
0.18
N/A
0.69 (0.33–1.45)
.31
GHR
rs6878512
IVS3− 21121 C/T
0.15
0.16
1.54 (1.04–2.27)
0.23
N/A
0.68 (0.34–1.38)
.005
GHR
rs68975302
IVS3− 21055 T/C
0.26
N/A
1.54 (1.06–2.23)
0.54
N/A
0.97 (0.42–2.28)
<.0001
GHR
rs61792
G186G
0.26
0.29
1.46 (1.01–2.11)
0.60
0.64
0.91 (0.33–2.48)
<.0001
GHR
rs29727802
IVS8 + 1229 C/T
0.25
0.26
1.50 (1.04–2.17)
0.58
N/A
0.78 (0.30–2.00)
<.0001
GHR
rs6180
Ex10 + 685 A/C
0.47
0.45
0.73 (0.48–1.10)
.06
0.35
0.29
1.00 (0.49–2.03)
.03
.003
SEPP1
rs6413428
Ex5 + 710 A/G
0.23
0.26
1.56 (1.08–2.26)
0.34
0.38
0.70 (0.34–1.42)
.002
SEPP1
rs7579
Ex5 + 626 C/T
0.28
0.30
1.08 (0.75–1.55)
.06
0.16
0.17
0.78 (0.37–1.66)
.25
.0009
1Adjusted for age at diagnosis/interview, smoking pack-year history, years of education, family history of lung cancer, history of COPD, adult aspirin use (never/ever), and BMI. 2Adjusted for multiple comparisons via the Benjamini and Hochberg False Discovery Rate (FDR) method. 3The minor allele differed for Caucasians and African Americans for the SNPs for which minor allele frequencies are bolded.